Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)

Over the past 3 years, there has been a marked increase in the number of PCT patents claiming structurally diverse TEAD - YAP/TAZ inhibitors, including filings by potentially new players. This trend highlights the growing recognition of the TEAD - YAP/TAZ axis as an attractive strategy for the development of new drugs, particularly for anti-cancer therapeutics.